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Highlights 
 GATA1 and FLI1 switch on the endogenous platelet factor 4 (Pf4) gene in 
fibroblasts 
 Pf4 expression is maintained and increases over time 
 PF4 protein is secreted and readily collected 
 A new technology for the generation of important biomolecules in heterologous cells 
 
Abstract 
The ability of transcriptional regulators to drive lineage conversion of somatic cells 
offers great potential for the treatment of human disease. To explore the concept of switching 
on specific target genes in heterologous cells, we developed a model system to screen 
candidate factors for their ability to activate the archetypal megakaryocyte-specific 
chemokine platelet factor 4 (PF4) in fibroblasts. We found that co-expression of the 
transcriptional regulators GATA1 and FLI1 resulted in a significant increase in levels of PF4, 
which became magnified over time. This finding demonstrates that such combinations can be 
used to produce potentially beneficial chemokines in readily available heterologous cell 
types.  
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Since Yamanaka’s pioneering discovery of cellular reprogramming of fibroblasts into induced 
pluripotent stem cells (Takahashi and Yamanaka, 2006; Yamanaka, 2008), attention in the field has 
been aimed towards uncovering combinations of factors that can directly convert differentiated cells 
from one lineage to another. However, the downstream applications of transdifferentiation remain 
restricted due to low conversion efficiency, safety concerns and phenotypic differences between target 
and reprogrammed tissues (Ma et al., 2013). Recognizing the challenges and limitations of cellular 
reprogramming, we decided to investigate whether defined factors can be used to initiate a specific 
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heterologous gene expression program with the aim of producing secretable, beneficial biomolecules 
such as growth factors, cytokines or hormones.  
 
To explore this strategy, we have developed a model cell-based assay system to assess candidate 
reprogramming factors for their ability to induce heterologous gene expression in fibroblasts. For the 
assay, we chose platelet factor 4 (PF4/CXCL4), an archetypal megakaryocyte chemokine with 
multiple roles in megakaryopoiesis (reviewed in (Kowalska et al., 2010)). Having selected a pool of 
candidate factors with key roles in megakaryocyte differentiation, we defined specific combinations 
capable of initiating a switch from a fibroblast to a more megakaryocyte-like gene expression 
program – namely, transcriptional regulators GATA1 and FLI1. We found that these factors induced 
significant levels of platelet factor 4, and furthermore showed that platelet factor 4 was abundantly 
secreted into the medium from the reprogrammed cells.  
 
To identify factors capable of inducing Pf4 gene expression, we used a candidate approach by 
selecting a pool of hematopoietic transcriptional regulators with known roles in megakaryopoiesis 
(Ferreira et al., 2005; Lu et al., 2004; Lulli et al., 2006; Shivdasani, 2001; Tijssen and Ghevaert, 
2013). Retroviral vectors encoding GATA1 (pMSCV-Hygro; Clontech), FLI1 and ETS1 
(pMSCV-Puro; Clontech) were constructed by inserting the coding sequence (GATA1) or open 
reading frame (FLI1 and ETS1) into the multiple cloning site. A lentiviral vector containing the 
coding sequence for FOG1 (pLV411; provided by Prof Thomas Gonda) was created using the 
Gateway PCR Cloning System and an LR Clonase II Enzyme mix kit (Life Technologies), according 
to manufacturer’s instructions. Retroviral and lentiviral constructs were transduced into murine 
embryonic fibroblasts (MEFs) with single and two factor combinations. Cells were maintained in 
DMEM containing 10% serum, 1000 U/L penicillin, 1 g/mL streptomycin, 2 mM L-glutamine and 
50 ng/mL recombinant human thrombopoietin (TPO) in addition to 2.5 g/mL puromycin or 500 
g/mL hygromycin where appropriate. To evaluate the potency of these factors, we extracted total 
RNA as described previously (Hancock et al., 2010) and used real time RT-PCR to assay for Pf4 gene 
expression (Ravid et al., 1991) (Fig. 1). Whilst no single factor enhanced Pf4 expression, through 
forced combinatorial expression we discovered that co-transduction of GATA1 and FLI1 resulted in a 
significant five-fold boost in Pf4 gene activity (primer sequences can be found in Table 1). To 
confirm this observation, we used antibiotic selection to generate stable cell lines expressing these 
factors and demonstrated high mRNA and protein expression of GATA1 and FLI1 (Fig. 2A-D).  
 
Table 1. Real time RT-PCR primer sequences 
 
Gene name 5’-3’ sequence 3’-5’ sequence 
18S rRNA CACGGCCGGTACAGTGAAAC AGAGGAGCGAGCGACCAA 
Gata1 AGCATCAGCACTGGCCTACT AGGCCCAGCTAGCATAAGGT 
Fli1 CAACCAGCCAGTGAGAGTCA GCCCACCAGCTTGTTACATT 
Pf4 GCGGTTCCCCAGCTCATAG CCGGTCCAGGCAAATTTTC 
 
Having established stably-expressing cell lines we examined Pf4 expression over time and 
observed a significant progressive elevation of Pf4 mRNA, comparable to expression seen in bone 
marrow (Fig. 3A). To assess whether sustained Pf4 activation translated into expression and secretion 
of protein, we assayed platelet factor 4 levels in cell culture media of control and GATA1/FLI1 MEFs 
using ELISA according to the manufacturer’s instructions (Quantikine, R&D Systems). Fig. 3B 
shows that while no PF4 is detected in the media of control cells, the addition of GATA1 and FLI1 
factors resulted in the secretion of high levels of the protein (>3 ng/mL).  
 
Additionally, microarrays were performed on GATA1/FLI1 cells and control cells four and 
seven months post-transduction (GEO accession no. GSE108983), to observe the extent of lineage 
reprogramming away from fibroblasts towards a megakaryocytic signature. These time points were 
chosen given that expression of our biomolecule of interest PF4 was most significantly upregulated 
following long-term overexpression of GATA1/FLI1. RNA at 50 ng/uL (total of 500 ng for each 
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sample) was provided to the Ramaciotti Centre for Genomics (UNSW Sydney) for hybridization to 
Affymetrix GeneChip® Mouse Gene 1.0 ST arrays and scanning, and analysis was carried out using 
Partek® Genomics SuiteTM software. Following co-transduction of GATA1/FLI1, we observed an 
increase in various megakaryocytic genes including Pf4 and Gp9, encoding the secreted chemokine 
platelet factor 4 and the megakaryocyte-specific surface marker CD42a, respectively. One the other 
hand, genes that were mostly down-regulated in the GATA1/FLI1 cells included many fibroblast-
specific genes such as Fbln5, Fbn1, Col5a, and Fgf2, suggesting that the GATA1/FLI1-expressing 
cells departed from a fibroblast-specific gene program. We compared upregulated genes in four- and 
seven-month GATA1/FLI1-transduced cells to a set of megakaryocytic-enriched genes derived from 
the Haemopedia Mouse RNA-Seq. This dataset is accessible at the Haemosphere online database 
(haemosphere.org) and contains the 100 most highly enriched genes in bone marrow-derived 
megakaryocytes cultured in TPO (de Graaf et al., 2016). We found that several of the most highly 
enriched megakaryocyte genes were upregulated in our GATA1/FLI1-transduced cells, indicating 
partial conversion and confirming an increase in expression of platelet factor 4 (Table 2). While we 
did not see comprehensive reprogramming towards the megakaryocytic lineage as others have 
observed (Moreau et al., 2016; Ono et al., 2012; Pulecio et al., 2016), we did identify a shift in gene 
expression away from the fibroblastic profile including, importantly, distinct upregulation of PF4.  
 
Table 2. Upregulated genes in GATA1/FLI1-transduced cells corresponding to the top 100 most 
highly-enriched genes from bone marrow-derived megakaryocytes (Haemopedia Mouse RNA-
Seq) 
 
Gene symbol (four months) FC* Gene symbol (seven months) FC* 
Podxl 11.5 Gm10419 12.3 
Casp4 4.5 Dusp4 10.3 
Dusp4 4.3 Podxl 10.2 
Gm10419 3.9 Casp4 6.8 
Tmem40 2.8 Clu 4.8 
  Pf4 4.3 
  Tmem40 4.2 
  Gp9 3.6 
*FC: fold change (GATA1/FLI1-transduced compared to empty vector) 
  
Having determined that forced expression of GATA1 and FLI1 can redirect fibroblasts to 
express platelet factor 4, we decided to investigate the potential of replacing GATA1 with a naturally 
occurring mutant form of the protein that lacks the N-terminal activation domain but retains the 
ability to bind DNA and interact with the GATA1 cofactor FOG (Wechsler et al., 2002). While 
GATA1 promotes megakaryocyte differentiation, this short form of GATA, termed GATA1s, has 
been shown to maintain megakaryocyte progenitor proliferation (Kuhl et al., 2005; Muntean and 
Crispino, 2005). In defining factors capable of switching on the expression of cytokines in 
heterologous cells, we reasoned that the inclusion of a gene regulatory protein that promotes 
progenitor proliferation might ultimately prove beneficial in enhancing the population size of 
transdifferentiating cells. 
 
To confirm that GATA1s can substitute for GATA1 in our experiments, we first transduced 
MEFs with GATA1s and FLI1 to generate stable cell lines and compared expression of critical 
megakaryocyte genes such as Pf4, Itgb3 and Gp9 in these cells with lines expressing only GATA1 
and FLI1. We found that substitution of GATA1 by GATA1s resulted in a significant increase in Pf4 
and Gp9 mRNA, while leading to similar levels of Itgb3, encoding the megakaryocyte surface marker 
CD61 (Fig. 4A-C). These data demonstrate that GATA1s has the potential to substitute for GATA1 to 
work in combination with FLI1 to initiate a shift in the cellular gene expression programme in 
fibroblasts leading to upregulation of platelet factor 4. 
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Here, we have screened candidate factors for their potential to reprogram murine embryonic 
fibroblasts to produce the megakaryocyte-specific cytokine platelet factor 4. In refining our choice of 
reprogramming factors, we found that GATA1s, a short mutant form of the protein (Zheng and 
Blobel, 2010), can substitute for GATA1, again working synergistically with FLI1 to drive expression 
of megakaryocyte-specific genes in fibroblasts. Given that GATA1s promotes lineage differentiation 
while still maintaining cellular proliferation (Muntean and Crispino, 2005), such alternative forms of 
reprogramming factors could be preferable in strategies aimed at establishing sizeable pools of 
cytokine producing cells.  
 
In addition to upregulating Pf4 gene activity, we found that forced expression of GATA1 and 
FLI1 in our fibroblast lines was accompanied by increased expression of other megakaryocyte genes, 
such as Itgb3 and Gp9, in line with partial reprogramming toward a megakaryocyte-like phenotype. 
This shift towards the megakaryocyte lineage corroborates recent research proposing a role for 
GATA1 and FLI1 in megakaryocyte forward programming (Moreau et al., 2016). However, it is 
apparent in our case that reprogramming is incomplete. We did not observe definitive morphological 
changes consistent with a megakaryocyte-like phenotype (data not shown), indicating that genetic 
barriers to further reprogramming remain in place. This suggests that additional or alternative 
combinations of factors are required to complete transdifferentiation of fibroblasts into 
megakaryocyte-like cells. However, we have shown that targeted addition of transcription factors can 
shift fibroblasts towards a more functional megakaryocytic state with the capacity to produce platelet 
factor 4 en masse. 
 
The candidate factors used in this screen were chosen largely due to known roles either in 
directing haematopoietic progenitors toward the megakaryocyte lineage, in megakaryocyte progenitor 
proliferation or in megakaryocyte differentiation. While GATA1 and FLI1 have been reported as 
inducers of megakaryocyte gene expression (Wang et al., 2002), our study is the first to identify that 
these factors drive the expression of platelet factor 4, a megakaryocyte-restricted biomolecule.  
 
In this study, we have determined that combinatorial forced expression of the transcriptional 
regulators GATA1 and FLI1 is capable of megakaryocyte specific reprogramming, which can have 
beneficial implications. The ability to switch on the Pf4 gene to manipulate levels of this cytokine 
may have future therapeutic applications, given its multiple roles in maintaining hemostasis and 
managing thrombosis (Kowalska et al., 2010). Furthermore, PF4 has recently been shown to be a 
component of a negative paracrine regulatory circuit that controls haematopoietic stem cell numbers 
within specific niches in the bone marrow (Bruns et al., 2014). The identification of factors that drive 
increased Pf4 expression may therefore prove useful in the treatment of disease states where low 
levels of the cytokine are associated with deregulated HSC proliferation and blood cancer (Aivado et 
al., 2007). It is encouraging for future applications that we were able to confirm that gene regulatory 
proteins with known roles in megakaryopoiesis are capable of activating megakaryocyte-specific gene 
expression in fibroblasts. These findings provide a proof of concept for the use of reprogramming 
factors to readily generate accessible beneficial biomolecules, and the success of this strategy suggests 
that continued research in this area may define a wide range of combinatorial factors capable of 
driving expression of a variety of beneficial biomolecules in heterologous cell types. 
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Fig. 1. Co-transduction of GATA1 and FLI1 promote Pf4 gene expression in fibroblasts. Real time 
RT-PCR was used to assess mRNA levels of Pf4 in MEFs transduced with candidate transcription 
factors or empty vector (EV). Expression levels were normalised to 18S rRNA and are shown relative 
to cells transduced with EV controls, with the EV mean value being set to 1.0. The mean for two to 
three independent experiments is shown as a horizontal line.  
 
 
 
Fig. 2. Stable expression of Gata1 and Fli1 in fibroblasts. MEFs were stably transduced with 
pMSCV-Hygro-Gata1 or pMSCV-Puro-Fli1 and expression of Gata1 (A) and Fli1 (B) were 
confirmed by real time RT-PCR, normalised to levels of 18S rRNA and with EV set to 1. Horizontal 
lines represent the mean of two independent experiments. Nuclear extracts were also prepared from 
stably transduced cells to assess GATA1 (D) and FLI1 (E) protein levels by Western blot with 
normalisation to β-actin. Anti-GATA1 N6 (Santa Cruz) and anti-FLI1 C-19 (Santa Cruz) were used to 
probe for each protein respectively. Two independent cell lines of EV (lanes 1 and 2) and 
GATA1/FLI1-transduced MEFs (lanes 3 and 4) were used for Western blots.  
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Fig. 3. Increasing long-term expression of platelet factor 4 in GATA1/FLI1 stable cell lines. (A) Pf4 
gene expression was determined by real time RT-PCR at the indicated time points, following stable 
transduction of MEFs with pMSCV-Hygro-Gata1 and pMSCV-Puro-Fli1. Bone marrow (BM) was 
used as a positive control. Expression levels were normalised to 18S rRNA and are shown relative to 
cells transduced with EV (set to 1 at each time point). Error bars represent standard error of the mean. 
(B) Secreted platelet factor 4 levels in GATA1/FLI1-transduced MEFs were compared to EV controls 
by quantitative ELISA (R&D Systems). Means are representative of two independent samples, shown 
by a horizontal line. 
 
 
Fig. 4. GATA1s can substitute for GATA1 in driving megakaryocyte gene expression. (A) Expression 
levels of Pf4 (A), Itgb3 (B) and Gp9 (C) after three weeks in MEFs transduced with either pMSCV-
Hygro-Gata1 and pMSCV-Puro-Fli1 or pMSCV-Hygro-Gata1s and pMSCV-Puro-Fli1 were 
normalised to levels of 18S rRNA. EV cell lines were transduced with pMSCV-Hygro or pMSCV-
Puro and set to 1, with means represented by horizontal lines.  
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